STOCK TITAN

[Form 3] SOLENO THERAPEUTICS INC Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Soleno Therapeutics (SLNO)no securities beneficially owned, with no non-derivative or derivative holdings listed. It was filed by one reporting person and includes an Exhibit 24 Power of Attorney authorizing the signatory.

Soleno Therapeutics (SLNO)) ha presentato una dichiarazione iniziale Form 3 per un amministratore al 13 ottobre 2025. La dichiarazione riporta nessun titolo detenuto beneficialmente, senza partecipazioni non derivati né derivati elencate. È stata presentata da una sola persona segnalante e include un Exhibit 24 Power of Attorney che autorizza il firmatario.

Soleno Therapeutics (SLNO)) presentó un Formulario 3 de declaración inicial para un director a partir del 13 de octubre de 2025. La presentación informa ningún valor mobiliario poseído beneficiosamente, sin participaciones no derivadas ni derivadas listadas. Fue presentada por una única persona reportante e incluye un Exhibit 24 Power of Attorney que autoriza al signatario.

Soleno Therapeutics (SLNO))가 2025년 10월 13일 기준으로 이사를 위한 Form 3 초기 진술서를 제출했습니다. 이 보고서는 수익상 소유 증권 없음을 보고하며 비파생 또는 파생 보유가 나열되지 않았습니다. 보고자는 한 명이며 서명을 허가하는 Exhibit 24 Power of Attorney를 포함합니다.

Soleno Therapeutics (SLNO)) a déposé un Formulaire 3 initial pour un administrateur au 13 octobre 2025. Le dépôt indique aucun titre détenu bénéficiairement, sans détentions non dérivées ni dérivées répertoriées. Il a été déposé par une seule personne déclarant et comprend une Exhibit 24 Power of Attorney autorisant le signataire.

Soleno Therapeutics (SLNO)) hat am 13. Oktober 2025 einen Form 3-Initialbericht für einen Direktor eingereicht. Die Einreichung meldet keine wirtschaftlich berechtigten Wertpapiere, wobei keine nicht-derivativen oder derivativen Positionen aufgeführt sind. Sie wurde von einer meldenden Person eingereicht und enthält eine Exhibit 24 Power of Attorney, die den Unterzeichner bevollmächtigt.

Soleno Therapeutics (SLNO)) قدمت نموذج Form 3 الأولي لمدير اعتباراً من 13 أكتوبر 2025. تقارير البيانات تفيد لا توجد أوراق مالية مملوكة Beneficially، مع عدم وجود حيازات غير مشتقة أو مشتقة مدرجة. تم تقديمها بواسطة شخص واحد من الأشخاص المبلغ عنهم وتشتمل على Exhibit 24 Power of Attorney يخوّل الموقّع.

Soleno Therapeutics (SLNO)) 已于 2025 年 10 月 13 日就一位董事提交初始 Form 3 声明。该申报显示无受益所有的证券,未列出非衍生或衍生持有。由一名申报人提交,并包含授权签署人的Exhibit 24 Power of Attorney

Positive
  • None.
Negative
  • None.

Soleno Therapeutics (SLNO)) ha presentato una dichiarazione iniziale Form 3 per un amministratore al 13 ottobre 2025. La dichiarazione riporta nessun titolo detenuto beneficialmente, senza partecipazioni non derivati né derivati elencate. È stata presentata da una sola persona segnalante e include un Exhibit 24 Power of Attorney che autorizza il firmatario.

Soleno Therapeutics (SLNO)) presentó un Formulario 3 de declaración inicial para un director a partir del 13 de octubre de 2025. La presentación informa ningún valor mobiliario poseído beneficiosamente, sin participaciones no derivadas ni derivadas listadas. Fue presentada por una única persona reportante e incluye un Exhibit 24 Power of Attorney que autoriza al signatario.

Soleno Therapeutics (SLNO))가 2025년 10월 13일 기준으로 이사를 위한 Form 3 초기 진술서를 제출했습니다. 이 보고서는 수익상 소유 증권 없음을 보고하며 비파생 또는 파생 보유가 나열되지 않았습니다. 보고자는 한 명이며 서명을 허가하는 Exhibit 24 Power of Attorney를 포함합니다.

Soleno Therapeutics (SLNO)) a déposé un Formulaire 3 initial pour un administrateur au 13 octobre 2025. Le dépôt indique aucun titre détenu bénéficiairement, sans détentions non dérivées ni dérivées répertoriées. Il a été déposé par une seule personne déclarant et comprend une Exhibit 24 Power of Attorney autorisant le signataire.

Soleno Therapeutics (SLNO)) hat am 13. Oktober 2025 einen Form 3-Initialbericht für einen Direktor eingereicht. Die Einreichung meldet keine wirtschaftlich berechtigten Wertpapiere, wobei keine nicht-derivativen oder derivativen Positionen aufgeführt sind. Sie wurde von einer meldenden Person eingereicht und enthält eine Exhibit 24 Power of Attorney, die den Unterzeichner bevollmächtigt.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Hahn Mark W

(Last) (First) (Middle)
100 MARINE PARKWAY, SUITE 400

(Street)
REDWOOD CITY CA 94065

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/13/2025
3. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney
No securities are beneficially owned.
/s/ Anish Bhatnagar, Attorney-in-Fact 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does SLNO’s Form 3 disclose?

It reports a director with no securities beneficially owned as of October 13, 2025.

What is the event date on the SLNO Form 3?

The event date is October 13, 2025.

Does the SLNO Form 3 list any non-derivative or derivative holdings?

No. No non-derivative or derivative holdings are listed.

How many reporting persons are on this SLNO Form 3?

It was filed by one reporting person.

Does the SLNO Form 3 include a Power of Attorney?

Yes. It includes Exhibit 24 – Power of Attorney.
Soleno Therapeutics Inc

NASDAQ:SLNO

SLNO Rankings

SLNO Latest News

SLNO Latest SEC Filings

SLNO Stock Data

3.61B
51.74M
1.79%
110.24%
14.27%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
Link
United States
REDWOOD CITY